Robert Menardi, DVM, brings extensive experience and knowledge to the company that offers Synovetin OA
Exubrion Therapeutics has named Robert Menardi, DVM, its Chief Veterinarian. He will manage the company’s veterinary technical training and awareness programs, in addition to serving as a subject matter expert for members of the veterinary field.
According to a company statement,1 Exubrion offers Synovetin OA, a canine elbow pain treatment that improves mobility and provides proven relief for up to 1 full year. The treatment is now available in more than 50 treatment centers across the United States, as more clinics continue to acquire it.
“We are very pleased to have someone with such technical veterinary experience join our team,” Peter Selover, CEO of Exubrion, said in the release. “As our product becomes more available nationwide, we are fortunate to have someone with the vast experience leading our veterinary services.
Previously, Menardi held a comparable position at Canopy Animal Health in Duluth, Georgia. Previously, he held various positions with Merial Limited (now Boehringer-Ingelheim Animal Health) from 2002. He was first a Technical Services Veterinarian and over the next 17 years became Technical Marketing Manager; Director of Field Veterinary Services, Operations and Professional Development; Companion Animal Vaccine Marketing Director; and Director of Veterinary Technical Solutions.1
Additionally, prior to Merial, Menardi was a practicing veterinarian in Eagle River, Alaska, and Flagstaff, Arizona, after earning his bachelor’s degree and DVM degree from Colorado State University.
“I am delighted to join the growing team at Exubrion,” commented Menardi. “Veterinary medicine needs more companies offering new, unique medical solutions to meet the unmet needs of companion animals. Exubrion and the Synovetin OA product offer veterinarians and their patients a truly new, convenient and long-lasting solution for chronic elbow pain and inflammation. ”
Dr. Robert Menardi joins Exubrion Therapeutics. Press release. Exubrion Therapeutics. May 25, 2022. Accessed May 26, 2022.